Midcareer Investigator Award

描述(由申请人提供)：这份职业生涯中期研究员奖申请寻求支持，为弗里德兰博士提供以患者为导向的研究(POR)的保护时间，并担任初级教员和每年1名研究员的研究导师。Freedland博士的POR专注于回溯性队列研究，过渡重点是前瞻性临床试验，旨在开发毒性较低的新疗法，以最大限度地减少前列腺癌治疗的副作用和减缓前列腺癌的进展。在这里，他提出了一项新的试验，将前列腺癌治疗后有PSA复发的男性的限制碳水化合物饮食与对照组进行比较，旨在减缓PSA上升的速度(延长PSA加倍时间)，作为减缓前列腺癌生长的间接指标。次要结果包括体重减轻和重要的前列腺癌生物标志物。这一奖项的成功完成将促进我们对前列腺癌的生活方式和其他低毒干预措施的理解，并有助于 培养下一代POR调查员。 公共卫生相关性：前列腺癌是主要的公共卫生负担。尽管付出了巨大的努力，也取得了一些进展，但今天，前列腺癌仍然是男性的第二大癌症杀手，也是发病率的重要来源。新的毒性较低的治疗方法旨在将治疗副作用降至最低，并在迫切需要的情况下减缓疾病进展。此外，还需要关注以患者为中心的研究(POR)的新一代调查人员。为此，这项职业生涯中期研究员奖申请寻求支持，为弗里德兰博士提供保护的POR时间，并担任初级教员的研究导师和每年1名研究员。虽然到目前为止，弗里德兰博士的POR主要集中在回溯性队列研究上，但这一奖项恰逢他的POR转向前瞻性临床试验，旨在开发毒性较低的新疗法，以最大限度地减少前列腺癌治疗的副作用和减缓前列腺癌的进展。此外，弗里德兰博士被证明是初级调查员培训方面的成功导师，这一奖项使他能够继续花费必要的时间指导和帮助培训下一代POR调查员。

DESCRIPTION (provided by applicant): This Midcareer Investigator Award application seeks support to provide Dr. Freedland with protected time for patient-oriented research (POR) and to act as research mentor for junior faculty and 1 research fellow per year. Dr. Freedland's POR focuses on retrospective cohort studies with a transitioning emphasis on prospective clinical trials aimed at developing new and less toxic treatments to minimize prostate cancer treatment side effects and slow prostate cancer progression. Herein, he proposes a new trial comparing a carbohydrate-restricted diet vs. control for men with PSA recurrence after prostate cancer therapy aiming to slow the rate of PSA rise (lengthen the PSA doubling time), as an indirect measure of slowed prostate cancer growth. Secondary outcomes include weight loss and important prostate cancer biomarkers. Successful completion of this award will advance our understanding of lifestyle and other low toxicity interventions for prostate cancer as well as help educate the next generation of POR investigators. PUBLIC HEALTH RELEVANCE: Prostate Cancer is a major public health burden. Despite great efforts, and some progress, today, prostate cancer remains the number two cancer killer of men and a significant source of morbidity. New and less toxic treatments aimed at both minimizing treatment side-effects and slowing disease progression at sorely needed. Moreover, a new generation of investigators focused on patient-oriented research (POR) is also needed. To these ends, this Midcareer Investigator Award application seeks support to provide Dr. Freedland with protected time for POR and to act as research mentor for junior faculty and 1 research fellow per year. While Dr. Freedland's POR focus to date has been largely on retrospective cohort studies, this award coincides with a shift in his POR toward prospective clinical trials aimed at developing new and less toxic treatments to minimize prostate cancer treatment side effects and slow prostate cancer progression. Moreover, Dr. Freedland is a proven successful mentor to junior investigators in training and this award allows him to continue to spend the time necessary to mentor and help train the next generation of POR investigators.